Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD Source: Eur Respir J 2007; 30: 472-478 Year: 2007
Tiotropium reduces COPD exacerbations: the MISTRAL study Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Influence of tiotropium bromid on airway inflammation and symptom in COPD patients Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Budesonide/formoterol significantly improves lung function and reduces exacerbations in both smokers and ex-smokers with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
frequent exacerbations of COPD are associated with severity of airflow limitation and chronic cough, sputum production. Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019
Replacing oxytropium with tiotropium significantly improves pulmonary function in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 213s Year: 2006
Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study Source: Eur Respir J 2014; 43: 1599-1609 Year: 2014
Tiotropium in COPD patients Source: Breathe 2008; 5: 271 Year: 2009
Success rate and safety of sputum induction in severe exacerbations of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 93s Year: 2002
Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005
Sputum induction in severe exacerbations of asthma: safety of a modified method Source: Eur Respir J 2011; 38: 979-980 Year: 2011
Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Absence of sputum eosinophils in subjects with symptomatic asthma on inhaled budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 274s Year: 2002
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013